Last update: 28/02/2019, Dr. Miguel B. Royo Salvador, Medical Board number 10389. Neurosurgeon y Neurologist.
Fibromyalgia, or Fibromyalgia Syndrome, has an overall incidence in the population between 1% and 8% and mostly affects the female gender. The Fibromyalgia Syndrome is considered to be primary, or idiopathic, when it is not associated to any other condition; it is defined as secondary when its diagnosis is related to other clinical conditions (mainly chronic diseases).
In 1984 the pathological concept of Central Sensitivity Syndromes was introduced to include different processes with common characteristics, such as Fibromyalgia, Chronic Fatigue Syndrome and others.
Fibromyalgia is characterized by a chronic widespread musculoskeletal pain (in muscles and/or bones), associated to stiffness and extra-skeletal symptoms that affect different organs and systems. The most frequent among these symptoms are: bowel pain, headache, tachycardia, menstrual disorders, shortness of breath, insomnia, anxiety, low mood and depression, cognitive deficits in memory, attention and concentration. It is also defined by intense tiredness and easy fatigability.
To date there are no recognized specific causes for Fibromyalgia. As far as research is concerned:
-According to the Filum System® health method:
In this last case, we observe that in some cases Fibromyalgia may be due a congenital mechanism of growth asynchrony, in the embryonic stage, between the spinal cord and the central nervous system on one hand and the spine on the other. This generates an abnormal spinal cord traction that is transmitted through an overly short and tense filum terminale, from the coccyx up to the cranium. Therefore we consider that the abnormal traction exerted by the Filum terminale can be a predisposing cause for the development of the Fibromyalgia Syndrome.
Fibromyalgia symptoms tend to appear and disappear cyclically. This, together with the lack of knowledge on the specific tests required to detect it, make its diagnosis difficult, with the consequent delay in the application of treatments, even conservative ones.
In 1990, the American College of Rheumatology established the diagnostic criteria for Fibromyalgia Syndrome currently accepted. In 2010 they introduced new criteria that are pending validation.
In Fibromyalgia, non-specific alterations have been observed in functional Nuclear Magnetic Resonance and corresponding to other clinical pictures of chronic pain, such as: change in the volume of grey and white matter, in N-acetylaspartate, choline or glutamate levels, mainly in the hippocampus, insula, prefrontal and cingulate cortex.
Given the observed correspondence between several cases of Fibromyalgia and the Filum Disease diagnosis, the Filum System® recommends to proceed to a brain and full spine Nuclear Magnetic Resonance. This way, the presence of signs of an abnormal traction of the spinal cord can be tested as a possible alteration, visible through neuroimaging, of the Fibromyalgia Syndrome.
The main risk factors predisposing to the development of Fibromyalgia are:
This condition does not have a definitive cure. To date, its treatment is performed in order to palliate pain, treat some other symptoms and obtain an improvement in the patients’ quality of life. The treatment of Fibromyalgia Syndrome today involves several specialties: internal and general medicine, rheumatology, rehabilitation, physiotherapy, psychology, dietetics etc.
As far as our specialty – Neurosurgery – is concerned, with the 2015 study published by Dr. Mantia and his collaborators, and based on the application of the Filum System®, they confirmed that the surgical approach applied to Fibromyalgia before physical therapy can improve the patient’s conditions. This may happen once the existence of signs of Filum Disease has been previously confirmed, as etiologically corresponding to the syndrome in at least a subset of cases.
Since 1993, with the publication of Dr Royo-Salvador’s doctoral thesis, which links the caudal traction of the entire nervous system due to the filum terminale to being the cause of several conditions, a new treatment has been designed. It is in this case etiological (cause-related) since the caudal cord traction force responsible for the pathological mechanism is eliminated by surgically sectioning the filum terminale.
Our technique for the sectioning of the Filum terminale (SFT) is minimally invasive and it is usually indicated as soon as possible in all cases, from mildly to severely symptomatic, as its risks are minimal, and it stops the condition’s progression.
1. Eliminates the traction of the spinal cord caused by the ligament when it is too short or tense.
2. The surgical time with ICSEB’s own minimally invasive technique is of 45 minutes. Few hours of hospitalisation. Local anaesthesia. Short post-operative period with no limitation. No need of admission in Intensive Care Unit. No blood transfusions.
3. Its application involves a mortality rate of 0%, with no sequelae.
4. Improves the symptoms and stops the evolution of the conditions related to the Filum Disease.
Patients with Fibromyalgia who underwent the surgical sectioning of the Filum Terminale according to the Filum System® method, followed by rehabilitation, showed significant improvements compared to patients treated exclusively with physical therapy.
After physical therapy, patients who underwent surgery experienced a great improvement of symptoms in terms of reduced pain and better quality of life.
Our English Department is at your disposal to help you with your enquiries.
All consultations received through this form or through the different email addresses of the 'Institut Chiari & Siringomielia & Escoliosis de Barcelona' are derived to the medical team to be studied and are supervised by Dr. Miguel B. Royo Salvador.
* It is imperative to tick this box.
Monday to Thursday: 9-18h (UTC +1)
Friday: 9-15h (UTC +1)
Saturday and Sunday closed
Pº Manuel Girona 16,
Barcelona, España, CP 08034
The Institut Chiari & Siringomielia & Escoliosis de Barcelona (ICSEB) complies with the established in EU regulation 2016/679 (GDPR).
The contents of this website are a non-official translation of the original content of the website in Spanish. The translation is courtesy of the Institut Chiari & Siringomielia & Escoliosis de Barcelona with the purpose of facilitating comprehension for anyone who wishes to Access the website.